Company: NDRA
Filing Date: 2025-04-07
Form Type: 10-K/A
Source: 0001654954-25-003937
Chunk: 15

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-04-07
Form: 10-K/A
Chunk 15
---
 the 1 share of common stock into which the outstanding shares of Series A Preferred Stock are convertible and does include shares of common stock due to exercise of warrants), .488 shares of Series A Preferred Stock, and no shares of Series B Preferred Stock or Series C Preferred Stock issued and outstanding, and a stock payable balance of $.

| F-9 |

During the year ended December 31, 2024, the Company issued a total of shares of its common stock, as follows:

Registered offering (described below):

| · | 3,490 shares of its common stock in return for aggregate net proceeds of $728,503 under the Placement Agreement;                                                                                                     |
| · | 31,666 shares of its common stock upon exercise of pre-funded warrants for aggregate net proceeds of $6,609,831 under the Placement Agreement (includes net proceeds from sale and exercise of pre-funded warrants); |

Other issuances:

| · | 68 shares of its common stock upon warrant exercises for aggregate net proceeds of $77,419;                                   |
| · | 181 shares of its common stock in return for aggregate net proceeds of $419,967 under the June 2021 ATM Agreement;            |
| · | 5 shares of its common stock upon conversion of 123.909 shares of its Series A Preferred Stock; and                           |
| · | 46 shares of the previously issued restricted common stock vested. The shares were issued for services and valued at $80,000. |
| · | 39 shares of common stock issued as beneficial round up shares as a result of our reverse stock splits                        |

Series B warrant exercises:

| · | 495,476 shares of its common stock upon cashless exercise of Series B Warrants |

During the year ended December 31, 2023, the Company issued a total of shares of its common stock, as follows:

| · | 2,464 shares of its common stock in return for aggregate net proceeds of $4,712,750 in a registered underwritten offering that closed on May 2, 2023; |
| · | 757 shares of its common stock in return for aggregate net proceeds of $1,770,643 under the June 2021 ATM Agreement;                                  |
| · | 905 upon warrant exercises for an aggregate net proceeds of $1,014,859.                                                                               |

Registered Offering

On June 4, 2024, the Company entered into a placement agency agreement (the “Placement Agreement”) with Craig-Hallum